NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT
GHENT, Belgium, 22 May 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has completed the preparation of a pre-clinical package for a novel Nanobody® (ALX-1141) in osteoarthritis. As part of the ongoing collaboration between …